THE WOODLANDS, Texas, April 14, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has reached the enrollment goal of 120 subjects in the first of two previously announced head-to-head studies comparing Androxal to the leading US testosterone replacement therapy. The two studies were initiated on January 12, 2014.
Help employers find you! Check out all the jobs and post your resume.
